InflaRx NV Stock Quote IFRX - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

2.46

Bid

2.35

Ask

2.64

Volume

0.00 Day's Range 0.00

1.165 52 Week Range 2.57

Market Cap

144.853M

Previous Close

2.46

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

173,111

Shares Outstanding

58,883,272

Dividend Yield

PE Ratio

-3.39

Earnings Per Share (EPS)

-0.72

Revenue

63k

Net Profit

-42.67M

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator in... InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.inflarx.de

Headquarters

Jena, Deu

Founded

InflaRx NV is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IFRX. The last closing price for InflaRx NV was $2.46. Over the last year, InflaRx NV shares have traded in a share price range of $ 1.165 to $ 2.57.

InflaRx NV currently has 58,883,272 shares outstanding. The market capitalization of InflaRx NV is $144.85 million. InflaRx NV has a price to earnings ratio (PE ratio) of -3.39.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable interim analysis, with guidance for trial size adaptation or futility expected by the...

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

JENA, Germany, Oct. 31, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.41	20	2.05	2.57	2.01	368273	2.26050974	CS
4	0.86	53.75	1.6	2.57	1.48	368014	1.99985456	CS
12	0.94	61.8421052632	1.52	2.57	1.36	173111	1.85845876	CS
26	1.01	69.6551724138	1.45	2.57	1.23	125076	1.75820258	CS
52	1.11	82.2222222222	1.35	2.57	1.165	184733	1.6307987	CS
156	-2.2	-47.2103004292	4.66	7.2499	0.7762	413217	3.79814678	CS
260	-0.94	-27.6470588235	3.4	9.7	0.7762	595767	4.24922981	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AALAmerican Airlines Group Inc	$ 14.52 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 68.24 (0.00%)	0
AADIAadi Bioscience Inc	$ 2.34 (0.00%)	0
AACGATA Creativity Global	$ 1.01 (0.00%)	0
AALAmerican Airlines Group Inc	$ 14.52 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 68.24 (0.00%)	0
AADIAadi Bioscience Inc	$ 2.34 (0.00%)	0
AACGATA Creativity Global	$ 1.01 (0.00%)	0
AALAmerican Airlines Group Inc	$ 14.52 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 68.24 (0.00%)	0
AADIAadi Bioscience Inc	$ 2.34 (0.00%)	0
AACGATA Creativity Global	$ 1.01 (0.00%)	0